Shopping Cart 0
Cart Subtotal
USD 0

Female Fertility Rapid Tests - Medical Devices Pipeline Assessment, 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Female Fertility Rapid Tests-Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, Female Fertility Rapid Tests-Medical Devices Pipeline Assessment, 2018" provides an overview of Female Fertility Rapid Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Female Fertility Rapid Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Female Fertility Rapid Tests under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Female Fertility Rapid Tests and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry.

Reasons to buy

The report enables you to-

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Female Fertility Rapid Tests under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date.

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 4

2 Introduction 5

2.1 Female Fertility Rapid Tests Overview 5

3 Products under Development 6

3.1 Female Fertility Rapid Tests-Pipeline Products by Stage of Development 6

3.2 Female Fertility Rapid Tests-Pipeline Products by Segment 7

3.3 Female Fertility Rapid Tests-Pipeline Products by Territory 8

3.4 Female Fertility Rapid Tests-Pipeline Products by Regulatory Path 9

3.5 Female Fertility Rapid Tests-Pipeline Products by Estimated Approval Date 10

4 Female Fertility Rapid Tests-Pipeline Products under Development by Companies 11

4.1 Female Fertility Rapid Tests Companies-Pipeline Products by Stage of Development 11

4.2 Female Fertility Rapid Tests-Pipeline Products by Stage of Development 12

5 Female Fertility Rapid Tests Companies and Product Overview 13

5.1 BBB Technologies Inc Company Overview 13

5.1.1 BBB Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 13

5.2 Bio-Alternative Medical Devices Ltd Company Overview 17

5.2.1 Bio-Alternative Medical Devices Ltd Pipeline Products & Ongoing Clinical Trials Overview 17

5.3 ET Healthcare, Inc. Company Overview 19

5.3.1 ET Healthcare, Inc. Pipeline Products & Ongoing Clinical Trials Overview 19

5.4 NG Biotech Company Overview 23

5.4.1 NG Biotech Pipeline Products & Ongoing Clinical Trials Overview 23

5.5 OPKO Health Inc Company Overview 26

5.5.1 OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview 26

5.6 Pop Test LLC Company Overview 27

5.6.1 Pop Test LLC Pipeline Products & Ongoing Clinical Trials Overview 27

5.7 Quidel Corp Company Overview 28

5.7.1 Quidel Corp Pipeline Products & Ongoing Clinical Trials Overview 28

6 Female Fertility Rapid Tests- Recent Developments 29

6.1 Jun 22, 2018: Bob Schruender, CEO Joins Sekisui Medical Board of Directors 29

6.2 Jun 14, 2018: FIRST TO KNOW Whole Blood, Rapid Pregnancy Test from NOW Diagnostics Available Over-The-Counter in Italy 29

6.3 May 08, 2018: Quidel Announces First Quarter 2018 Financial Results 30

6.4 Apr 25, 2018: NanoRepro Increases Sales and Achieves Positive Operating Result (EBITDA) 31

6.5 Apr 10, 2018: NanoRepro Reaches Its Annual Targets and Wants to Grow Strongly in 2018 31

6.6 Feb 21, 2018: Quidel Reports Fourth Quarter and Full Year 2017 Financial Results 32

6.7 Feb 19, 2018: Quidel to establish new Business Service Centre in Galway city 34

6.8 Dec 05, 2017: Lia Diagnostics Announces FDA Clearance Of The First And Only Flushable, Biodegradable Pregnancy Test 35

6.9 Dec 05, 2017: NanoRepro With Higher Sales and Better Results 36

6.10 Nov 01, 2017: Quidel Reports Third Quarter 2017 Financial Results 36

6.11 Oct 11, 2017: Aided by provincial government, Sekisui completes renovation and announces expansion 38

6.12 Sep 29, 2017: Alere Announces the U.S. Department of Justice Closes Investigation 39

6.13 Sep 28, 2017: Alere Announces Settlement with SEC 39

6.14 Aug 03, 2017: Alere Reports Second Quarter 2017 Financial Results 39

6.15 Aug 03, 2017: NanoRepro Increases Growth in the Second Quarter 40

6.16 Jul 26, 2017: Quidel Reports Second Quarter 2017 Financial Results 40

7 Appendix 42

7.1 Methodology 42

7.2 About GlobalData 45

7.3 Contact Us 45

7.4 Disclaimer 45


List Of Figure

1.2 List of Figures

Figure 1: Female Fertility Rapid Tests-Pipeline Products by Stage of Development 6

Figure 2: Female Fertility Rapid Tests-Pipeline Products by Segment 7

Figure 3: Female Fertility Rapid Tests-Pipeline Products by Territory 8

Figure 4: Female Fertility Rapid Tests-Pipeline Products by Regulatory Path 9

Figure 5: Female Fertility Rapid Tests-Pipeline Products by Estimated Approval Date 10


List Of Table

1.1 List of Tables

Table 1: Female Fertility Rapid Tests-Pipeline Products by Stage of Development 6

Table 2: Female Fertility Rapid Tests-Pipeline Products by Segment 7

Table 3: Female Fertility Rapid Tests-Pipeline Products by Territory 8

Table 4: Female Fertility Rapid Tests-Pipeline Products by Regulatory Path 9

Table 5: Female Fertility Rapid Tests-Pipeline Products by Estimated Approval Date 10

Table 6: Female Fertility Rapid Tests Companies-Pipeline Products by Stage of Development 11

Table 7: Female Fertility Rapid Tests-Pipeline Products by Stage of Development 12

Table 8: BBB Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 13

Table 9: Mobile RDT Reader-Alpha-fetoprotein Test-Product Status 13

Table 10: Mobile RDT Reader-Alpha-fetoprotein Test-Product Description 14

Table 11: Mobile RDT Reader-FSH Test-Product Status 14

Table 12: Mobile RDT Reader-FSH Test-Product Description 14

Table 13: Mobile RDT Reader-Luteinizing Hormone Test-Product Status 15

Table 14: Mobile RDT Reader-Luteinizing Hormone Test-Product Description 15

Table 15: Mobile RDT Reader-Serum/Urine Based HCG Test-Product Status 15

Table 16: Mobile RDT Reader-Serum/Urine Based HCG Test-Product Description 16

Table 17: Mobile RDT Reader-Urine Based HCG Test-Product Status 16

Table 18: Mobile RDT Reader-Urine Based HCG Test-Product Description 16

Table 19: Bio-Alternative Medical Devices Ltd Pipeline Products & Ongoing Clinical Trials Overview 17

Table 20: Digital Strip Reader-Fertility-Product Status 17

Table 21: Digital Strip Reader-Fertility-Product Description 17

Table 22: Digital Strip Reader-Pregnancy Testing-Product Status 18

Table 23: Digital Strip Reader-Pregnancy Testing-Product Description 18

Table 24: ET Healthcare, Inc. Pipeline Products & Ongoing Clinical Trials Overview 19

Table 25: Pylon Assay-Estrogen-Product Status 19

Table 26: Pylon Assay-Estrogen-Product Description 19

Table 27: Pylon Assay-Follicle Stimulating Hormone-Product Status 20

Table 28: Pylon Assay-Follicle Stimulating Hormone-Product Description 20

Table 29: Pylon Assay-Luteinizing Hormone-Product Status 20

Table 30: Pylon Assay-Luteinizing Hormone-Product Description 21

Table 31: Pylon Assay-Progesterone-Product Status 21

Table 32: Pylon Assay-Progesterone-Product Description 21

Table 33: Pylon Assay-Prolactin-Product Status 22

Table 34: Pylon Assay-Prolactin-Product Description 22

Table 35: NG Biotech Pipeline Products & Ongoing Clinical Trials Overview 23

Table 36: BB-Blood Precision hCG Test-OTC-Product Status 23

Table 37: BB-Blood Precision hCG Test-OTC-Product Description 23

Table 38: hCG Monitor-Product Status 24

Table 39: hCG Monitor-Product Description 24

Table 40: NG-Quant hCG-Product Status 24

Table 41: NG-Quant hCG-Product Description 25

Table 42: NG-Test hCG Pregnancy Termination-Product Status 25

Table 43: NG-Test hCG Pregnancy Termination-Product Description 25

Table 44: OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview 26

Table 45: Diagnostic Assay-Fertility-Product Status 26

Table 46: Diagnostic Assay-Fertility-Product Description 26

Table 47: Pop Test LLC Pipeline Products & Ongoing Clinical Trials Overview 27

Table 48: Pregnancy Pop Test-Product Status 27

Table 49: Pregnancy Pop Test-Product Description 27

Table 50: Quidel Corp Pipeline Products & Ongoing Clinical Trials Overview 28

Table 51: Sofia hCG Quant Assay-Product Status 28

Table 52: Sofia hCG Quant Assay-Product Description 28

Table 53: Glossary 44

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

BBB Technologies Inc, Mobile RDT Reader - Alpha-fetoprotein Test; BBB Technologies Inc, Mobile RDT Reader - FSH Test; BBB Technologies Inc, Mobile RDT Reader - Luteinizing Hormone Test; BBB Technologies Inc, Mobile RDT Reader - Serum/Urine Based HCG Test; BBB Technologies Inc, Mobile RDT Reader - Urine Based HCG Test; Bio-Alternative Medical Devices Ltd, Digital Strip Reader - Fertility; Bio-Alternative Medical Devices Ltd, Digital Strip Reader - Pregnancy Testing; ET Healthcare, Inc., Pylon Assay - Estrogen; ET Healthcare, Inc., Pylon Assay - Follicle Stimulating Hormone; ET Healthcare, Inc., Pylon Assay - Luteinizing Hormone; ET Healthcare, Inc., Pylon Assay - Progesterone; ET Healthcare, Inc., Pylon Assay - Prolactin; NG Biotech, BB-Blood Precision hCG Test - OTC; NG Biotech, hCG Monitor; NG Biotech, NG-Quant hCG; NG Biotech, NG-Test hCG Pregnancy Termination; OPKO Health Inc, Diagnostic Assay - Fertility; Pop Test LLC, Pregnancy Pop Test; Quidel Corp, Sofia hCG Quant Assay


Companies

BBB Technologies Inc

Bio-Alternative Medical Devices Ltd

ET Healthcare, Inc.

NG Biotech

OPKO Health Inc

Pop Test LLC

Quidel Corp